ISIS 2302

Oligo-TCS

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Glover JM, Leeds JM, Mant TGK, et al. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J Pharmacol Exp Ther 1997 Sep; 282: 1173–80
PubMed CAS Google Scholar
Media Release: Isis Pharmaceuticals, 15 Jul 1996
Google Scholar
Lappin J, Podbielski J, Welsh M, et al. A phase I study: the side-effect profile of an intercellular adhesion molecule-1 antisense phosphorothioate oligodeoxynucleotide, ISIS 2302. Transplantation 1998 Jun 27; 65: S63
Article Google Scholar
Henry SP, Larkin R, Novotny WF, et al. Effects of ISIS 2302, a phosphorothioate oligonucleotide, on in vitro and in vivo coagulation parameters. Pharm Res 1994 Oct; 11 Suppl.: 353
Google Scholar
Bowen-Yacyshyn MB, Shanahan W, Bennett F, et al. Antisense to ICAM-1 affects the peripheral blood expression and intestinal expression of adhesion molecules in Crohn’s disease. Gastroenterology 1998 Apr; 114 Suppl.: 940, Part 2
Article Google Scholar
Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 1998 Jun; 114: 1133–42
Article PubMed CAS Google Scholar

ISIS 2302. Drugs R&D 1, 265–267 (1999). https://doi.org/10.2165/00126839-199901030-00018

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.